stocks logo

VYNE

Vyne Therapeutics Inc
$
0.403
-1.037(-72.014%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.418
Open
0.3851
VWAP
--
Vol
16.78M
Mkt Cap
24.00M
Low
0.370
Amount
--
EV/EBITDA(TTM)
--
Total Shares
14.53M
EV
-4.21M
EV/OCF(TTM)
--
P/S(TTM)
101.41
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
150.00K
-24.24%
--
--
175.00K
+44.63%
--
--
175.00K
+108.33%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for VYNE Therapeutics Inc. (VYNE) for FY2025, with the revenue forecasts being adjusted by 40% over the past three months. During the same period, the stock price has changed by -69.68%.
Revenue Estimates for FY2025
Revise Upward
up Image
+40%
In Past 3 Month
Stock Price
Go Down
down Image
-69.68%
In Past 3 Month
3 Analyst Rating
up Image
1181.92% Upside
Wall Street analysts forecast VYNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYNE is 5.17 USD with a low forecast of 4.50 USD and a high forecast of 6.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image
1181.92% Upside
Current: 0.403
sliders
Low
4.50
Averages
5.17
High
6.00
H.C. Wainwright
H.C. Wainwright
Neutral
downgrade
2025-04-25
Reason
H.C. Wainwright lowered the firm's price target on VYNE Therapeutics to $4.50 from $5.75 and keeps a Neutral rating on the shares after the FDA placed a clinical hold on the company;s Phase 1b study evaluating VYN202 in moderate-to-severe plaque psoriasis. The firm finds it important that there have been no serious adverse events observed in subjects that have been enrolled in the Phase 1b study to date. It should also be underscored that this clinical hold only applies to the VYV202 program, the analyst tells investors in a research note. VYNE's ongoing Phase 2b trial assessing repibresib gel in nonsegmental vitiligo continues without interruption, contends H.C. Wainwright.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$5.75
2025-03-06
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$5.75
2025-01-14
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$5.75
2025-01-06
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$5.75
2024-12-23
Reason
BTIG
Julian Harrison
Strong Buy
Initiates
$8
2024-11-18
Reason
BTIG initiated coverage of VYNE Therapeutics with a Buy rating and $8 price target.

Valuation Metrics

The current forward P/E ratio for Vyne Therapeutics Inc (VYNE.O) is -1.57, compared to its 5-year average forward P/E of -2.14. For a more detailed relative valuation and DCF analysis to assess Vyne Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.14
Current PE
-1.57
Overvalued PE
-0.66
Undervalued PE
-3.61

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.04
Current EV/EBITDA
0.57
Overvalued EV/EBITDA
1.31
Undervalued EV/EBITDA
-1.22

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
56.14
Current PS
40.55
Overvalued PS
104.22
Undervalued PS
8.06

Financials

Annual
Quarterly
FY2025Q1
YoY :
+106.12%
202.00K
Total Revenue
FY2025Q1
YoY :
+24.62%
-9.20M
Operating Profit
FY2025Q1
YoY :
+37.85%
-8.60M
Net Income after Tax
FY2025Q1
YoY :
+33.33%
-0.20
EPS - Diluted
FY2025Q1
YoY :
+43.59%
-11.46M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-5.67%
-6.21K
FCF Margin - %
FY2025Q1
YoY :
-33.12%
-4.26K
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
43.8K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

VYNE News & Events

Events Timeline

2025-07-30 (ET)
2025-07-30
08:21:08
New
VYNE says Phase 2B trial with repibresib gel did not meet primary endpoint
select
2025-07-02 (ET)
2025-07-02
11:02:09
H.C. Wainwright 'encouraged' by VYNE Therapeutics VYN202 update
select
2025-07-02
07:49:07
VYNE Therapeutics provides program update on VYN202 following clinical hold
select
Sign Up For More Events

News

4.0
07-11Yahoo Finance
VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress
9.0
06-26NASDAQ.COM
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
9.0
04-25Benzinga
FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold
Sign Up For More News

FAQ

arrow icon

What is Vyne Therapeutics Inc (VYNE) stock price today?

The current price of VYNE is 0.4033 USD — it has decreased -72.01 % in the last trading day.

arrow icon

What is Vyne Therapeutics Inc (VYNE)'s business?

arrow icon

What is the price predicton of VYNE Stock?

arrow icon

What is Vyne Therapeutics Inc (VYNE)'s revenue for the last quarter?

arrow icon

What is Vyne Therapeutics Inc (VYNE)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Vyne Therapeutics Inc (VYNE)'s fundamentals?

arrow icon

How many employees does Vyne Therapeutics Inc (VYNE). have?

arrow icon

What is Vyne Therapeutics Inc (VYNE) market cap?